Alzheimer disease relation to p53

Hypothesis 1

Restoring the functional p53-GAP-43 signaling axis by inhibiting the Amyloid-beta-induced HIPK2-MT2A cascade will reverse synaptic gene downregulation and axonal regeneration deficits in Alzheimer's disease models.

Mechanistic rationale

• Exposure to nanomolar concentrations of soluble Amyloid-beta (Aβ) 1-40 induces the proteasomal degradation of homeodomain-interacting protein kinase 2 (HIPK2). (Direct; PMID: 20418953)
• The depletion of HIPK2 leads to the significant upregulation of metallothionein 2A (MT2A), a potent zinc chelator. (Direct; PMID: 20418953)
• Upregulated MT2A removes the zinc atom required as a cofactor for p53 DNA-binding, resulting in the formation of a conformationally altered, unfolded, and transcriptionally inactive p53 protein. (Derived; PMID: 20418953, PMID: 10.1186/s13195-020-00732-0)
• A functional p53-CBP/p300 transcription module is explicitly required for the expression of Growth-Associated Protein 43 (GAP-43), which mediates axonal outgrowth and regeneration. (Direct; PMID: 19057620)
• In Alzheimer's disease (AD), the prevalence of unfolded p53 is directly linked to the downregulation of GAP-43 and subsequent synaptic impairment. (Direct; PMID: 10.1186/s13195-020-00732-0)
• The chaperone-associated E3 ligase CHIP can stabilize p53's native conformation under stress and promotes the degradation of BACE1, the rate-limiting enzyme for Aβ generation. (Direct; PMID: 25773675)
• Taken together, these mechanisms suggest that Aβ-driven p53 misfolding is a rate-limiting step in synaptic failure that can be bypassed by regulating the HIPK2-MT2A zinc-shuttling mechanism. (Derived; PMID: 20418953, PMID: 19057620, PMID: 25773675)

Predictions

• Pharmacological or genetic inhibition of MT2A will increase the recruitment of p53 to the GAP-43 promoter in neurons exposed to Aβ. (Derived; PMID: 20418953, PMID: 19057620)
• Zinc supplementation (100 µM) will reduce the levels of unfolded p53 (detected by PAb240 antibody) and simultaneously restore GAP-43 mRNA and protein levels. (Derived; PMID: 20418953, PMID: 10.1186/s13195-020-00732-0)
• Overexpression of CHIP will synergize with zinc supplementation to decrease BACE1 levels and increase neurite length in AD models. (Derived; PMID: 25773675, PMID: 19057620)

Study design

The study will utilize primary rat cortical neurons (PMID: 25773675) treated with 10 nM Aβ 1-40 to induce p53 misfolding (PMID: 20418953). Perturbations will include: 1) siRNA-mediated knockdown of MT2A, 2) supplementation with Zinc Chloride (100 µM), and 3) lentiviral delivery of wild-type p53 or CHIP. Readouts will encompass p53 conformational immunoprecipitation (PAb1620 vs. PAb240), Chromatin Immunoprecipitation (ChIP) for p53 binding to the GAP-43 promoter, RT-qPCR for GAP-43 and BACE1 mRNA, and morphometric analysis of neurite outgrowth and synapse density using synaptophysin staining (PMID: 19057620, PMID: 20418953). (Derived; PMID: 20418953, PMID: 25773675, PMID: 19057620)

Confounders & controls

• Endogenous zinc levels in standard culture media must be precisely controlled as they influence basal p53 folding (Direct; PMID: 20418953). (Direct; PMID: 20418953)
• Proteasome activity levels, which regulate both HIPK2 and p53 degradation, should be monitored using inhibitors like MG132 (Direct; PMID: 20418953). (Direct; PMID: 20418953)
• Isogenic p53-null cell lines (e.g., Saos-2) will serve as negative controls for p53-dependent transcriptional effects (Direct; PMID: 1905840). (Direct; PMID: 1905840)

Risks/limitations

• Zinc can facilitate the precipitation of Aβ into amorphous aggregates, which might mask the intracellular benefits of zinc on p53 (Direct; PMID: 20418953). (Direct; PMID: 20418953)
• p53 gain-of-function (GOF) mutations in certain models could lead to neomorphic properties that interfere with canonical GAP-43 regulation (Direct; PMID: 30915036). (Direct; PMID: 30915036)
• The efficacy of restoring p53 may be limited in late-stage AD models where widespread neuronal loss has already occurred (Derived; PMID: 10.1186/s13195-020-00732-0). (Derived; PMID: 10.1186/s13195-020-00732-0)

Falsification criteria

• If zinc supplementation restores p53 DNA-binding but fails to upregulate GAP-43 mRNA or improve neurite outgrowth, the hypothesis is falsified (Derived; PMID: 19057620). (Derived; PMID: 19057620)
• If MT2A knockdown does not restore p53's wild-type conformation in the presence of Aβ, the proposed zinc-chelation mechanism is invalid (Derived; PMID: 20418953). (Derived; PMID: 20418953)